Agarwal emphasized that safe drug administration and toxicity management require coordinated action across multiple levels of ...
Gotistobart reduced the risk of death by 54% and doubled 12-month survival compared with chemotherapy in previously treated ...
Anu Agarwal, vice president of global cancer support at the American Cancer Society, outlined key barriers facing oncology ...
Nuvalent has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib for the ...
Among patients receiving metformin, Lac-Phe levels rose and remained elevated even after hormone therapy began. However, the ...
Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.
Vaccination: HPV vaccination remains a primary target for eliminating cervical cancer. While the WHO goal is 90% coverage, global rates hover around 25%. However, in Ethiopia, cervical cancer ...
The 2026 NCCN updates represent a convergence of biological precision and patient-driven lifestyle changes. By integrating ...
Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...
A multidisciplinary panel of experts at the NCCN 2026 Annual Conference highlighted the shifting demographic of oncology, ...
Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing ...
Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing comorbidities when selecting ARPI doublets for older patients with prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results